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Mesalamine (5-aminosalicylic acid, 5-ASA) is used because of its
local effects in the treatment of inflammatory bowel disease. Therefore,
the aims of this work were to compare and validate three analytical
methods for the quality control of commercial coated tablets containing
5-ASA: high performance liquid chromatography (HPLC), 1,1-
diphenyl-2-picrylhydrazyl radicals (DPPH•) and nitrosation. The
parameters linearity, precision and accuracy were studied in this work.
HPLC with ultraviolet detection at 254 nm was carried out with a
C18 column and a mobile phase constituted of 30 mmol/L monobasic
phosphate buffer (pH 7.0) and methanol (70:30; v/v), with 25%
tetrabutylammonium hydrogen sulphate. The DPPH• method was
performed at 517 nm and using 100 mmol/L acetate buffer, pH 5.5,
ethanol and 250 μmol/L ethanolic solution of DPPH•. The nitrosation
method was accomplished by using a platinum electrode and standard
0.1 mol/L sodium nitrite as titrant solution. Repeatability (intra-day)
and intermediate precision (inter-day), expressed as RSD, were lower
than 3%. The experimental recoveries were between 72.5 and 99.9%.
Statistical analysis by one-way ANOVA, followed by the multiple
comparison test of Bonferroni showed no significant difference among
the three methods. All proposed methods can be used for the reliable
quantitation of 5-ASA in pharmaceutical dosage forms.
INTRODUCTION
Mesalamine (5-aminosalicylic acid, 5-ASA) (Figure
1) is used for its local effects in the treatment of inflammatory
bowel disease, including ulcerative colitis and Crohn’s
disease (Cai et al., 2003; Gotti et al., 2001). Despite the fact
that it has been used for over 50 years, the mechanism of
action of this drug remains uncertain. 5-ASA has been shown
to be a potent scavenger of reactive oxygen species that play
a significant role in the pathogenesis of inflammatory bowel
disease, inhibition of natural killer cell activity, inhibition of
antibody synthesis, inhibition of cyclo-oxygenase and
lipoxygenase pathways and impairment of neutrophil
function (Geier, Miner, 1992; Palumbo et al., 1995).
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This drug is unstable under gastric conditions and
prone to be absorbed in the upper intestine, which causes
low drug bioavailability and low efficiency against
inflammatory colon disease. Therefore, colon-specific
delivery of 5-ASA is an important issue (Cai et al., 2003).
Among 5-ASA colon-specific prodrugs, the earliest
accepted drug is sulfasalazine, an azo-conjugate of 5-ASA
with sulfapyridine, but this drug presents adverse effects
due to sulfapyridine. Four novel delivery mechanisms have
been developed to delay the release of 5-ASA until it
reaches the colonic site of inflammation: (1) 5-ASA
conjugated to an inert molecule; (2) 5-ASA conjugated to
an other 5-ASA molecule; (3) 5-ASA enveloped in a
delayed-release coating and (4) 5-ASA enveloped in a pH-
sensitive coating (Cai et al., 2003; Geier, Miner, 1992).
Polymeric prodrugs with 5-ASA can successfully
deliver 5-ASA to the colon (Cai et al., 2003). Asacol®, an
oral commercial formulation containing 400 mg of 5-ASA
coated with acrylic resin (Eudragit S resin), delivers the
drug at alkaline pH (Riley, Turnberg, 1990).
Since the drug is widely used in the treatment of
inflammatory bowel disease, it is important to compare and
validate analytical methods for its determination in
pharmaceutical dosage forms.
Current literature reports few methods to quantify 5-
ASA in pharmaceutical dosage forms. A HPLC method
adopted by the United States Pharmacopoeia 24 ed. is
based on the mobile phase containing tetrabutylammonium
hydrogen sulphate as an ion-pairing agent, which shortens
column life. Moreover, mobile phase preparation requires
tedious procedures.
On the other hand, the structural characteristic of 5-
ASA allows the use of other quantitative methods. Since
antioxidant properties have been attributed to 5-ASA
because it is a phenolic compound (Dinis, Madeira,
Almeida, 1994), antioxidant activity can be used as an
indirect method for 5-ASA quantitation. The DPPH•
method is economic, simple, rapid and widely used to de-
termine the antioxidant activity of phenolic compounds. A
nitrosation method can be used to classify amines as
primary (-NH2), secondary (-NHR), or tertiary (-NR2).
The derivative products change according to whether the
amine being tested is aliphatic or aromatic, and according
to its substitutions. Primary aromatic amines react with
nitrous acid to form diazonium salts, which are stable at
0 °C but decompose to nitrogen gas at room temperature.
Due to the formation of a diazonium salt, the method can
be used as a quantitative method, applying potenciometric
titration. It is a simple procedure and a reproducible
method.
The present work reports the comparison and
validation of the HPLC, DPPH• and nitrosation methods to
quantify 5-ASA in coated tablets (Asalit® 400 mg). The
work describes analytical parameters that are very
important for the validation of an analytical procedure,
such as accuracy and specificity.
MATERIAL AND METHODS
Chemical
A 5-ASA reference standard was obtained from
Acros Organics (New Jersey, USA). The pharmaceutical
dosage form (Asalit® 400mg) containing 5-ASA was kindly
supplied by Galena (Campinas, SP, Brazil). All other
reagents used were of pharmaceutical grade or HPLC gra-
de. All solutions were prepared daily.
Experimental apparatus and analytical condition
The HPLC method was performed on a LC-10AT
(Shimadzu Corporation, Tokyo, Japan) equipped with a
20 µL loop and SPD-10A UV/VIS detector (Shimadzu).
Integration of the chromatographic peaks was achieved with
C-R6A Chromatopac integrator (Shimadzu). The analysis
was performed by using a SuperPac Sephasil C18 column
(particle size: 5 μm; 250 x 4.0 mm i.d.; SuperPac Sephasil),
and samples were isocratically eluted with a 30 mmol/L
monobasic phosphate buffer (pH 7.0) and methanol (70:30;
v/v), containing 25% tetrabutylammonium hydrogen
sulphate, with the flow rate set at 1.0 mL/min. Each sample
was filtered prior to injection using a Millex LCR filter
(Millipore Corporation, São Paulo, SP, Brazil) and a 20 μL
aliquot was injected into the HPLC apparatus with UV
detection at 254 nm (USP 24, 2000).
The DPPH• method was performed on a UV-VIS
Spectrophotometer U2001 (Hitachi) at 517 nm, using 1.0
cm quartz cells. The antioxidant activity was determined by
the hydrogen-donating ability of 5-ASA. For radical
scavenging activity measurements, 1 mL of 100 mmol/L
FIGURE 1 - Structure of 5-ASA.
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acetate buffer, pH 5.5, 1 mL of ethanol, 0.5 mL of
250 μmol/L ethanolic solution of DPPH•  was mixed, and
10 μL of different concentrations of 5-ASA were added.
The absorbance was measured after 10 min at 517 nm,
according to the method described by Dinis et al (1994).
The blank was prepared from the reaction mixture without
DPPH• solution. All measurements were performed in
triplicate.
The nitrosation method was conducted according to
Korolkovas (1988). The potentiometric titration
procedure was carried out using a platinum electrode as
indicator electrode and a Micronal B374 pHmeter was
used.
0.1 mol/L sodium nitrite solution was used as titrant.
Mesalamine samples was dissolved in 0.005 mol/L HCl
and cooled in an ice bath. The samples were titrated with
0.1 mol/L sodium nitrite and the diazonium salts formed
were determined potentiometrically.
Preparation of the standard solutions and sample
solutions
Preparation of tablet samples
In order to acquire the sample solutions, 5 coated
tablets were individually accurately weighted and their
average weight was estimated. These 5 tablets were
triturated one at a time to a powder. The remaining blended
powder was used to prepare the sample solutions.
HPLC method
An amount of tablets powder corresponding to 25
mg of mesalamine was weighted and diluted to obtain a
solution with 10 μg/mL final concentration in the mobile
phase solution. The analytical curve was prepared with
standard mesalamine in final concentrations of
0.25-100 μg/mL, originally acquired from a 1000 μg/mL
mesalamine stock solution. All samples were prepared in
triplicate.
1,1-diphenyl-2-picrylhydrazyl radical (DPPH•) method
Coated powdered samples were weighted to obtain
the equivalent to 50 mg of mesalamine, and this powder
was diluted with a 30 mmol/L monobasic phosphate
buffer (pH 7.0) and methanol (70:30; v/v), containing
25% tetrabutylammonium hydrogen sulphate in order to
obtain a 500 μg/mL. 10 μL this solution was used for the
reactions in order to obtain a 2  mg/mL mesalamine
solution. The analytical curve was prepared with
standard mesalamine in the concentration range of
0.4 – 4 μg/mL in the reaction medium. All samples were
prepared in triplicate.
Nitrosation method
Accurately weighted amounts of tablets powder
equivalent to 100 mg of mesalamine were diluted with
0.005 mol/L HCl (and deionized water). The solution was
cooled in an ice bath. A potentiometric titration procedure
was performed by reaction of the aromatic amine
(mesalamine) with the titrant solution (0.1 mol/L of sodium
nitrite) in order to produce N-nitrosamines (diazonium
salts). Low temperatures are required in the procedure to
avoid diazonium salt decomposition. A platinum electrode
was used as indicator electrode. A 100 mg mesalamine
reference standard underwent the same sample treatment as
the analyzed sample. The analyses were conducted in
triplicate.
Method validation
Linearity
The analytical curve was obtained with different
concentrations (10 for HPLC and 6 for DPPH•) of the
standard solution (0.25 – 100 μg/mL for HPLC method and
0.4 – 3 μg/mL for the DPPH• method). The solutions were
prepared in triplicate. The linearity was evaluated by line-
ar regression analysis (Raggi et al., 2000).
Since the titration methods do not need an analytical
curve, linearity was not estimated for nitrosation method.
Precision
The precision of the assay was determined by
repeatability (intra-day) and intermediate precision (inter-
day). Repeatability was evaluated by assaying samples at
same concentration during the same day. Intermediate
precision was studied by comparing the assays on different
days (3 days). Six sample solutions (10 μg/mL for HPLC
method, 2 μg/mL for DPPH• method and 100 mg for
nitrosation method) were prepared (Mendez, Steppe,
Schapoval, 2003).
Accuracy
The accuracy was determined by recovery of known
amounts of 5-ASA reference standard added to the samples
at the beginning of the process. Established amounts of
standard mesalamine were added to known amounts of
triturated coated Asalit® tablets powder to obtain 3 different
concentration of addition. Samples were assayed and
recovery percentages for each standard concentration were
estimated. The analyses were carried out in triplicate (Gotti
et al., 2001).
The recovery percentage of the 5-ASA standard
added was calculated using the equation proposed by
AOAC (1990).
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RESULTS AND DISCUSSION
HPLC method
HPLC is method widely used in the quality control of
drugs. Several HPLC methods have been used to measure the
concentration of 5-ASA in biological fluids (Gotti et al., 2001).
The HPLC method adopted by the United States
Pharmacopoeia uses a mobile phase containing tetrabutyl-
ammonium hydrogen sulphate as an ion-pairing agent
(USP 24, 2000). Although the column life is decreased by
that compound, the addition of tetrabutylamonium
hydrogen sulphate is important in order to improve the
separation due to the ion-par interactions of the ammonium
salts with the anionic solutes (Cendrowska et al., 1990).
Thus, 5-ASA present in coated tablet Asalit® 400 mg was
determined by the HPLC method proposed by the United
States Pharmacopoeia.
Figure 2 shows standard solution (A) and sample
solution (B) typical chromatograms obtained from the 5-
ASA analyses using the proposed method. As shown in the
results, the standard and sample solutions were eluted at the
same retention time (2.89 min) allowing a rapid deter-
mination of the drug, which is important for routine
analysis. The chromatograms present symmetrical peaks
and the base line was free of interference for both standard
and sample solutions. Cendrowska et al. (1990) examined
two HPLC methods to separate 5-ASA from other drugs,
and the retention time obtained was higher than 7 min.
Thus, the proposed methodology is faster than that
described by Cendrowska et al. (1990).
The analytical curve for 5-ASA was constructed by
plotting drug concentration versus peak height and showed
good linearity in the 0.25–100 μg/mL range. The
representative linear equation was y = 437.41x + 60.915,
with a correlation coefficient (r = 0.999) highly significant
for the method (Table I).
Method precision was determined by repeatability
(intra-day) and inter-day intermediate precision (inter-day)
tests and was expressed as RSD (relative standard deviation)
(%) of a measurement series. The analytical parameters
obtained for the determination of 5-ASA by the HPLC
method are presented in Table II. The experimental values
obtained over 3 days for a measurement series of a 10 µg/mL
solution showed 1.75% RSD, indicating good inter-day
precision. Intra-day variability showed a mean RSD of
2.51%. Haney and Dash (1997) validated the HPLC method
for 5-ASA assay and the intra and inter-day precisions
obtained were 1.2-4.6% and 1.1-3.5%, respectively.
The USP and AOAC indicate, in general, RSD
values lower 2% (AOAC, 1975; Parejo et al., 2000).
According to Raggi et al (2000) the RSD value should be
lower than 3%. Therefore, the precision of this method is
within the expected range.
The accuracy of the method was determined by
addition of three different concentrations of standard in the
samples, in triplicate, and the mean recovery percentage
was found to be 88.2% (Table III). In general, the recovery
percentage as a measure of the accuracy should be close to
100% (AOAC, 1975; Parejo et al., 2000).
1,1-diphenyl-2-picrylhydrazyl radicals (DPPH•) method
DPPH• is a stable free radical potentially reactive with
substances able to donate a hydrogen atom and, thus, useful
to assess antioxidant activity of specific compounds of extracts
(Dinis, Madeira, Almeida, 1994). Because of its odd electron,
DPPH• has a strong absorption band at 517 nm. Since this
electron becomes paired in the presence of a free radical
scavenger, the absorption decreases stoichiometrically with
respect to the number of electrons taken up. This change in
absorbance produced by this reaction has been widely used to
test the ability of several molecules to act as free radical
scavengers (Dinis, Madeira, Almeida, 1994).
Various investigations have shown that 5-ASA
presents antioxidant activity (Dinis, Madeira, Almeida,
1994) demonstrated the antioxidant activity of 5-ASA
compared to other antipyretic and anti-inflammatory drugs,
and indicated that 5-ASA acts as a potent free radical
scavenger, in a way similar to ascorbate, in contrast with
salicylate which does not react with DPPH•. Among the
compounds tested, 5-ASA presented the highest antioxidant
activity (Dinis, Madeira, Almeida, 1994).
FIGURE 2 - HPLC chromatograms of 5-ASA reference
standard (A) and 5-ASA present in coated tablet Asalit®
40 μg/mL (B).
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In the present study, the antioxidant activity was
determined by the ability of 5-ASA to donate hydrogen
atoms to DPPH•. It was utilized in order to quantify 5-ASA
in Asacol® 400 mg coated tablets, using spectrophotometric
methods, and this was compared to other methodologies
proposed to quantify 5-ASA.
5-ASA caused an instantaneous decrease in DPPH•
absorbance, when compared to the control absorbance,
suggesting that the commercial coated tablets present high
antioxidant activity.
A concentration-response curve was constructed by
plotting 5-ASA concentration versus free radical scavenger
activity and linearity was obeyed for the range of
0.4-3 µg/mL in the reaction medium. The representative
linear equation was y = 10.707x – 0.6435, with a
correlation coefficient of 0.999 (Table I).
Table II shows the analytical parameters obtained for
the determination of 5-ASA by the DPPH• method, using a
2 μg/mL solution in order to acquire the measurement
series. The results indicate satisfactory intra-day variability
TABLE III - Experimental values obtained in the recovery test for 5-ASA in commercially coated tablet
Method Sample concentration Concentration of % Recoverya ±
added standard RSD (%)
*HPLC 30 μg/mL 10 μg/mL 98.0 ± 4.63
30 μg/mL 20 μg/mL 75.5 ± 1.80
30 μg/mL 30 μg/mL 91.0 ± 2.00
*DPPH· 200 μg/mL 200 μg/mL 72.5 ± 2.00
200 μg/mL 300 μg/mL 82.5 ± 2.30
200 μg/mL 400 μg/mL 81.4 ± 1.38
Nitrosation 50 mg 30 mg 99.9 ± 1.60
50 mg 40 mg 97.9 ± 1.28
50 mg 50 mg 95.9 ± 1.80
a Mean of three determination; * Aliquot of 20 mL and 10 mL of the solutions were used for the HPLC and DPPH· methods,
respectively.
TABLE I - Regression analysis of the quantitation data of 5-ASA by two of the proposed methods
Statistical parameters HPLC Method DPPH• Method
Regression equationa y=437.41x + 60.915 y=10.707x – 0.6435
Standard error of slope 102.78 1.01
Standard error of intercept 1.88 0.00218
Correlation coefficient (r) 0.999 0.999
Concentration range (μg/mL) 0.25 – 100 0.4 - 3
y=ax + b, x is the concentration of the drug in μg/mL (HPLC method and DPPH• method) and y is peak high (HPLC
method) or antioxidant activity (DPPH• method); a Based on three calibration curves.
TABLE II - Analytical parameters obtained in validation of the proposed methods
HPLC (10 μg/mL) DPPH• (2 μg/mL) Nitrosation (100 mg)
mean 9.55 μg/mL 2.31 μg/mL 97.64 mg
SD 1.68 3.02 1.07
RSD (%) Intra-day 2.51 1.50 1.93
RSD(%) Inter-daya 1.75 2.60 1.09
SD = standard derivation, RSD = relative standard deviation in percentage; a3 days
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(1.50% RSD) and inter-day variability (2.60% RSD). The
accuracy of the method was determined. However, the
mean recovery percentage was 78.8% (Table III), which is
under the recommended recovery percentage value of
100%.
Nitrosation method
Amine nitrosation is a quantitative analytical
method that uses a standard sodium nitrite solution as
titrant. The titration is carried out an acidic environment.
Nitrous acid reacts quantitatively with aromatic amines
producing diazonium salts. Since it is a simple and
reproducible method, it can be used to quantify 5-ASA,
which is an aromatic amine, present in commercial coated
tablets.
Experimental data obtained when 5-ASA was
quantified through the nitrosation method were used to set
the analytical parameters show in Table II. The results
show a 1.11% RSD, pointing to a satisfactory intra-day
variability, and a 1.09% RSD inter-day variability. The
accuracy of the method was estimated and the mean
recovery percentage was found to be 97.2%.
Comparison between proposed methods
The proposed analytical methods were compared
using statistical analysis. Data were statistically analyzed
by one-way ANOVA, followed by the Bonferroni multiple
comparison test and do not show significant differences
among the methods, considering P > 0.05.
HPLC and DPPH• methods had very similar
precisions, both inside the acceptable limit. HPLC had a
better recovery percentage than DPPH•, which showed
recoveries under the limit suggested by AOAC (1975).
CONCLUSIONS
HPLC, DPPH• and nitrosation are all suitable
methods for a reliable quantitation of 5-ASA in
commercial coated tablets in terms of analytical
parameters. There were no significant statistical
differences among the proposed methods. It should be
noted that all methods showed similar and favorable
results with respect to precision and accuracy. The RSD
values are all lower than 3%. However, the nitrosation
method showed the best recovery percentage and it was
the most precise method, as well as being the simplest and
most inexpensive methodology. The proposed methods
have the advantage of using feasible analytical procedures
and need only a simple preparation of the samples.
Therefore, they can be used for the drug analysis in
routine quality control.
RESUMO
Validação dos métodos de CLAE, DPPH• e
nitrosação para determinação de mesalazina em
formas farmacêuticas
Mesalazina (ácido 5-aminosalicílico, 5-ASA) é utilizado
devido seu efeito local no tratamento de doença inflamató-
ria intestinal. Assim, o objetivo deste trabalho foi compa-
rar e validar três métodos analíticos para o controle de
qualidade de comprimidos comerciais revestidos contendo
5-ASA: cromatografia líquida de alta eficiência (CLAE),
radical 1,1-difenil-2-picril-hidrazil (DPPH•) e nitrosação.
Os parâmetros linearidade, precisão e exatidão foram es-
tudados neste trabalho. CLAE com detecção ultravioleta
em 254 nm foi realizada utilizando coluna C18 e a eluição
em fase móvel constituída de tampão fosfato monobásico
30 mmol/L (pH 7,0) e metanol (70:30; v/v), com 25% de
sulfato hidrogênio de tetrabutilamônio. Para o método de
DPPH• utilizou-se tampão acetato 100 mmol/L, pH 5,5,
álcool etílico e 250 μmol/L solução etanólica de DPPH• a
517 nm. Para o método de nitrosação utilizou-se um eletro-
do de platina e um padrão de nitrito de sódio 0.1 mol/L
como solução titulante. Repetibilidade (intra-dia) e preci-
são intermediária (inter-dia), expressado como DPR, foi
menor que 3%. A recuperação experimental foi entre 72,5
e 99,9%. Análise estatística por “one-way” ANOVA, segui-
da de comparação múltipla do teste de Bonferroni, não
mostrou significância entre os três métodos. Os métodos
propostos podem ser usados para análise quantitativa do5-
ASA em formas farmacêuticas.
UNITERMOS: Mesalazina. Cromatografia líquida de
alta eficiência. 1,1-difenil-2-picril-hidrazil. Nitrosação.
Validação. Forma farmacêutica.
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